The University of Queensland Diamantina Institute, Brisbane, Australia; Department of Otolaryngology, Princess Alexandra Hospital, Brisbane, Australia.
The University of Queensland Diamantina Institute, Brisbane, Australia.
Biochim Biophys Acta Rev Cancer. 2021 Apr;1875(2):188523. doi: 10.1016/j.bbcan.2021.188523. Epub 2021 Feb 16.
The natural history of adenoid cystic carcinoma (ACC) is relentless, defined by treatment failure heralded by locoregional recurrence and distant metastatic disease. In this review, we present an update of clinical features, molecular classification, current targeted therapies, immune landscapes and novel treatment targets with their respective clinical trials. The presented results are defined by a lack of overall response rate and limited progression free survival, with restriction to stable disease. In addition, ACC is resistant to immune checkpoint inhibition due to low tumour immunogenicity and lack of PD-L1 expression. Here we present a new prospective research paradigm for ACC, including the potential to target prostate specific membrane antigen (PSMA) and the potential for manipulation of target receptors in the clinic. The presentation of this review aims to promote future research to improve response rates and outcomes for therapeutics undergoing clinical trial in ACC.
腺样囊性癌（ACC）的自然病程是无情的，以局部区域复发和远处转移性疾病为标志的治疗失败预示着其病程。在这篇综述中，我们介绍了临床特征、分子分类、当前的靶向治疗、免疫景观以及具有相应临床试验的新的治疗靶点的最新进展。目前的结果以缺乏总体缓解率和有限的无进展生存期为特征，仅能达到疾病稳定。此外，由于肿瘤免疫原性低和缺乏 PD-L1 表达，ACC 对免疫检查点抑制具有耐药性。在这里，我们为 ACC 提出了一个新的前瞻性研究范例，包括靶向前列腺特异性膜抗原（PSMA）的潜力和在临床上操纵靶受体的潜力。本综述的目的是为未来的研究提供参考，以提高正在 ACC 中进行临床试验的治疗方法的反应率和结果。
